BioLineRx (NASDAQ:BLRX) Price Target Cut to $9.00 by Analysts at HC Wainwright

BioLineRx (NASDAQ:BLRX) had its target price reduced by HC Wainwright from $21.00 to $9.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.14) EPS and FY2025 earnings at ($0.13) EPS.

Separately, StockNews.com began coverage on shares of BioLineRx in a research report on Sunday, November 24th. They issued a “hold” rating on the stock.

BioLineRx Stock Performance

NASDAQ:BLRX opened at $0.29 on Monday. The company has a 50-day moving average of $0.47 and a 200-day moving average of $0.60. The firm has a market cap of $22.94 million, a price-to-earnings ratio of -1.30 and a beta of 1.48. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. BioLineRx has a twelve month low of $0.25 and a twelve month high of $1.89.

Hedge Funds Weigh In On BioLineRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. CVI Holdings LLC acquired a new stake in BioLineRx during the 2nd quarter worth about $462,000. PVG Asset Management Corp purchased a new position in shares of BioLineRx in the second quarter worth approximately $70,000. Finally, Atria Investments Inc raised its holdings in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the period. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.